Responses
Clinical pharmacy and clinical trials (including case series)
CPC-091 Natalizumab in Cypriot Patients with Relapsing Remitting Multiple Sclerosis: Three Year Data on Safety, Efficacy and Frequency of Anti-JC Virus Antibodies
Compose a Response to This Article
Other responses
No responses have been published for this article.